Trend/MAs: Bullish structure (SMA_5 > SMA_20 > SMA_200) suggests the broader trend is up.
Momentum: MACD histogram is positive (0.0337) but positively contracting, implying upside momentum is fading.
RSI: RSI_6 = 78.12 (stretched/near overbought), increasing odds of a pullback rather than a clean immediate continuation.
Levels: Pivot support ~1.35; near-term resistance R1 ~1.526 (price 1.50 is close), then R2 ~1.634.
Near-term pattern stats provided: only a modest projected upside (next day ~1.4%, next week ~3.26%, next month ~2.36%) and only 40% hit-rate—not compelling for an immediate entry near resistance.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Open interest is heavily skewed to calls (call OI 2183 vs put OI 18), signaling bullish positioning/hedging skew.
However, today's option volume is 0 (calls 0, puts 0), so the market isn’t actively expressing fresh conviction right now.
Volatility: 30D IV ~335.99% vs historical vol ~126.68% (very high option pricing); IV percentile ~41 suggests not extreme vs its own history, but still very elevated in absolute terms.
Takeaway: sentiment skew appears bullish (OI), but with no volume today it’s not a strong actionable signal.
Technical Summary
Sell
4
Buy
10
Positive Catalysts
Technical trend remains bullish on moving averages.
Call open-interest skew (very low put/call OI ratio) suggests market participants are positioned more for upside than downside.
Hedge funds/insiders: Neutral (no notable selling pressure flagged in the provided data).
Neutral/Negative Catalysts
while MACD is contracting—higher risk of a near-term pullback from current levels.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 0, down -100% YoY; Gross margin: 0, down -100% YoY (no operating revenue base shown in the snapshot).
Net income: -4.23M (still a loss), but improved materially YoY (loss narrowed vs prior year per the provided change).
EPS: -0.06 (still negative). Overall: financials do not support a momentum chase without a clear catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided in the dataset.
Wall Street pros/cons view cannot be validated from the given inputs; based on available fundamentals (no revenue, ongoing losses), the fundamental case is weak versus the technical uptrend.
Wall Street analysts forecast EQ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQ is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast EQ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQ is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 1.480
Low
0
Averages
0
High
0
0
Current: 1.480
Low
0
Averages
0
High
0
Jefferies
Buy
downgrade
$8 -> $4
AI Analysis
2025-08-20
Reason
Jefferies
Price Target
$8 -> $4
AI Analysis
2025-08-20
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Equillium to $4 from $8 and keeps a Buy rating on the shares. The company's recent $30M financing marks a new chapter as it pivots to a new lead pipeline asset, focused initially on the large commercial opportunity in ulcerative colitis, the analyst tells investors in a research note. The firm finds the pre-clinical data generated encouraging/supporting evidence and looks forward to the first-in-human trial set to start in mid-2026. Jefferies added that it updated its revenue model for EQ504 in moderate to severe UC, leading to the new price target.
Leerink Partners
Thomas Smith
Buy
to
Hold
Downgrades
$3 → $1
2025-03-28
Reason
Leerink Partners
Thomas Smith
Price Target
$3 → $1
2025-03-28
Downgrades
Buy
to
Hold
Reason
Leerink analyst Thomas Smith downgraded Equillium to Market Perform from Outperform with a price target of $1, down from $3. The company reported "disappointing" topline results from the Phase 3 EQUATOR study of its lead asset itolizumab in front-line acute graft-versus-host disease, the analyst tells investors in a research note. The firm says that while encouraging trends emerged with longer-term follow-up and the safety profile appears generally clean, it sees an uncertain path forward for itolizumab ahead of regulatory interactions expected in the next two months. Leerink cites uncertainty regarding the regulatory path forward and a financing overhang for the downgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EQ
